Form Type: 4

SEC EDGAR Link
Accession Number:0001179110-21-004126
Date:2021-04-01
Issuer: RIGEL PHARMACEUTICALS INC (RIGL)
Original Submission Date:

Reporting Person:

RODRIGUEZ RAUL R
RIGEL PHARMACEUTICALS, INC.
1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
STOCK OPTION (RIGHT TO BUY) 2.42 2021-04-01 deemed execution date A 162,500 (a) 2030-02-06 common stock 162,500 $2.42 162,500 direct
Footnotes
IDfootnote
f1 the reporting person was granted a performance-based option to purchase 162,500 shares of common stock on february 6, 2020. thus, the exercise price of this option is $2.42 (the closing price of the issuer's common stock on nasdaq the date of grant). in light of the performance-based vesting condition of this grant, the grant was not reportable under section 16 until the performance metric was satisfied. on april 1, 2021, it was determined that the performance metric had been met.
f2 the option was fully vested on april 1, 2021, the date the performance metric had been met.

Elevate your investments